{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.7","upperLimit":"95.2","value":"90.2"},{"groupId":"OG001","lowerLimit":"75.7","upperLimit":"95.5","value":"88.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Disease control rate (DCR) is the sum of complete response (CR), partial response (PR), and stable disease (SD) rates. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set includes all subjects for whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"9 months after the last participant is randomized or later to data cut off, up to approximately 35 months","title":"Disease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}